Actualités et événements

Halo Pharma Emerges as Standalone CDMO Following Siegfried Acquisition of Noramco Independent CDMO positioned for growth in sterile injectables and other complex drug product formats Over $30 million investment plan underway to establish sterile vial, prefilled syringe, and cartridge manufacturing in Whippany, NJ Lee Karras (previously CEO of Noramco) named Halo Pharma’s CEO to lead next phase of expansion Whippany, NJ – May 1, 2026 – Halo Pharma (the “Company”), a leading CDMO partner to the pharmaceutical industry and previous

Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals Weston, Florida and Whippany, New Jersey — April 14, 2026 – Apotex Corp. today announced that it has secured a strategic sterile filling partnership with Halo Pharmaceuticals through an investment that provides Apotex with access to a significant portion of the overall sterile injectable filling capacity currently being installed and qualified at Halo’s Whippany, New Jersey facility. This access is intended to support Apotex’s sterile injectable manufacturing network and signals

Halo Pharma Executive Chairman Lee Karras says escalating equipment and component costs are the two biggest challenges facing parenteral/sterile drug product manufacturers.

Whippany, NJ – January 27, 2026 SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The transaction is subject to customary closing conditions and regulatory approvals Halo Pharma, with sites in Whippany, NJ and Mirabel QC, will remain as a stand-alone company with a focus on growth as a drug product contract development and manufacturing organization (CDMO) Lee Karras will become CEO of Halo Pharma after the

Whippany, NJ – December 16, 2025 New addition enhances manufacturing continuity and supports seamless progression from early-phase development to late-stage production Macro-Pactor® to be online in Q1 2026 Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor®, a versatile roller compactor that enhances the company’s ability to manage complex formulations, improve process efficiency, and deliver consistent solid-dose pharmaceutical products.

Whippany, NJ – October 14, 2025 Malgouyres joins Halo with over 14 years of operational experience in the pharmaceutical industry As site director, he will oversee the operations of the Halo Mirabel cGMP manufacturing site Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, has appointed Laurent Malgouyres as Site Director for its cGMP facility in Mirabel, Quebec, Canada. In his new role, Malgouyres will oversee production, quality, and overall site performance. Malgouyres has worked in the